The main purposes of this study are: * to investigate the safety and tolerability of ACI-19764 when it is administered to healthy participants * to determine how quickly and to what extent ACI-19764 is absorbed, transported, metabolized, and excreted by the body (fasted and after a meal) * to determine the effect of ACI-19764 on specific markers in the blood that are part of the immune system The effects of ACI-19764 will be compared with the effects of a placebo. ACI-19764 is a brain-penetrant NLRP3 inhibitor. The study consists of 2 parts, Part A (SAD, single ascending dose) and Part B (MAD, multiple ascending doses). Participants in Part A will receive the study compound once and participants in Part B will receive the study compound multiple times (daily over 14 days). Each of these 2 study parts will be divided into different groups of participants to test different doses of ACI-19764.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs) assessed by intensity (mild, moderate or severe) and causal relationship (unrelated, unlikely related, possibly related or probably related)
Timeframe: From first study treatment administration up to the end of the safety follow-up (i.e. 21 to 24 days after Day 4 for study Part A and 21 to 24 days after Day 17 for study Part B)
Vital signs: Change from baseline in blood pressure
Timeframe: From baseline up to the end of the treatment and observation period (i.e. Day 4 for study Part A and Day 17 for study Part B)
Vital signs: Change from baseline in respiratory rate
Timeframe: From baseline up to the end of the treatment and observation period (i.e. Day 4 for study Part A and Day 17 for study Part B)
Vital signs: Change from baseline in pulse rate
Timeframe: From baseline up to the end of the treatment and observation period (i.e. Day 4 for study Part A and Day 17 for study Part B)
Vital signs: Change from baseline in body temperature
Timeframe: From baseline up to the end of the treatment and observation period (i.e. Day 4 for study Part A and Day 17 for study Part B)
ECG: Change from baseline in heart rate
Timeframe: From baseline up to the end of the treatment and observation period (i.e. Day 4 for study Part A and Day 17 for study Part B)
ECG: Change from baseline in PR interval
Timeframe: From baseline up to the end of the treatment and observation period (i.e. Day 4 for study Part A and Day 17 for study Part B)
ECG: Change from baseline in QRS interval
Timeframe: From baseline up to the end of the treatment and observation period (i.e. Day 4 for study Part A and Day 17 for study Part B)
ECG: Change from baseline in QT interval
Timeframe: From baseline up to the end of the treatment and observation period (i.e. Day 4 for study Part A and Day 17 for study Part B)
ECG: Change from baseline in QTcF interval
Timeframe: From baseline up to the end of the treatment and observation period (i.e. Day 4 for study Part A and Day 17 for study Part B)
ECG: Change from baseline in QTcB interval
Timeframe: From baseline up to the end of the treatment and observation period (i.e. Day 4 for study Part A and Day 17 for study Part B)
Number of participants reporting suicidal ideation or behavior using Columbia-Suicide Severity Rating Scale (C-SSRS)
Timeframe: From baseline up to the end of the treatment and observation period (i.e. Day 17)
Pharmacokinetic (PK) in plasma: Maximum observed concentration (Cmax), stratified by sex
Timeframe: From baseline to up to the end of the treatment and observation period (i.e. Day 4 for study Part A and Day 17 for study Part B)
Pharmacokinetic (PK) in plasma: Time to reach Cmax (tmax), stratified by sex
Timeframe: From baseline to up to the end of the treatment and observation period (i.e. Day 4 for study Part A and Day 17 for study Part B)
Pharmacokinetic (PK) in plasma: Area under the curve (AUC) from time zero to the last measured concentration above the limit of quantification (AUC 0-last)
Timeframe: From baseline to up to the end of the treatment and observation period (i.e. Day 4)
Pharmacokinetic (PK) in plasma: AUC from time zero to infinity (AUC 0-infinity)
Timeframe: From baseline to up to the end of the treatment and observation period (i.e. Day 4)
Pharmacokinetic (PK) in plasma: Terminal elimination half-life (t½)
Timeframe: From baseline to up to the end of the treatment and observation period (i.e. Day 4)
Pharmacokinetic (PK) in plasma: Dose proportionality for Cmax and AUC 0-infinity
Timeframe: From baseline to up to the end of the treatment and observation period (i.e. Day 4)
Pharmacokinetic (PK) in plasma: AUCtau (AUC of one dosing interval) after first and last study treatment administration, stratified by sex
Timeframe: From baseline to up to the end of the treatment and observation period (i.e. Day 17)
Pharmacokinetic (PK) in plasma: Terminal elimination half-life (t½) after last study treatment administration, stratified by sex
Timeframe: From baseline to up to the end of the treatment and observation period (i.e. Day 17)
Pharmacokinetic (PK) in plasma: Average plasma concentration at steady state (Cavg,ss) during the last dosing interval, stratified by sex
Timeframe: From baseline to up to the end of the treatment and observation period (i.e. Day 17)
Pharmacokinetic (PK) in plasma: Minimum plasma concentration at steady state (Cmin,ss) during the last dosing interval, stratified by sex
Timeframe: From baseline to up to the end of the treatment and observation period (i.e. Day 17)
Pharmacokinetic (PK) in plasma: Trough (pre-dose) plasma concentrations (Ctrough), stratified by sex
Timeframe: From baseline to up to the end of the treatment and observation period (i.e. Day 17)
Pharmacokinetic (PK) in plasma: Accumulation index (AI) for Cmax and AUCtau, stratified by sex
Timeframe: From baseline to up to the end of the treatment and observation period (i.e. Day 17)
Pharmacokinetic (PK) in CSF: Drug concentration at steady state (trough level capturing Cmin), stratified by sex
Timeframe: From baseline to Day 13